Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Sharon O'Toole

Snr Experimental Officer (Obstetrics)
TRINITY CENTRE, S J H

Senior Research Fellow (Histopathology)


Sharon O'Toole is a senior research fellow in Trinity College Dublin working in the area of ovarian cancer. She qualified with a BSc Hons in UCG in 1994 and then completed an MSc Biotechnology in 1996. Having worked in industry she then returned to research and completed a PhD in Trinity College in 2003. She has gained enormous experience in the area of ovarian cancer and has played a major role in the development of studies in gynaecological cancer. She was instrumental in establishing the DISCOVARY consortium which is a multidisciplinary and trans- institutional consortium dedicated to addressing the problems of ovarian and uterine cancer. The consortium manages the largest ovarian cancer bioresource in the country. The consortium has now merged to form INNOVATION- the Irish National Network for Ovarian Cancer Collaboration which has brought together the medical, research and charity organisations involved in ovarian cancer in Ireland. Her research interests centre around diagnostic and prognostic biomarkers and understanding the fundamental biology of the metastatic cascade and circulating tumour cells. She has been successful in identifying diagnostic and prognostic biomarkers for ovarian cancer and her ultimate aim is to translate these into the clinic. She has presented at both national and international conferences and published in peer-reviewed journals. She works closely with the 3 ovarian cancer charities in Ireland whose mission is to improve outcomes for ovarian cancer in Ireland. She was part of the organising committee of the first World Ovarian Cancer Day on May 8th in 2013 and this has now become an annual event.
  Gynaecology oncology   Obstetrics/Gynecology   Oestregens in age related urogenital diseases
 Identification of novel biomarkers in recurrent/chemoresistant ovarian cancer
 A Consortium of researchers dedicated to understanding and treatment of ovarian cancer: The DISCOVARY Consortium
 Ageing and the Urogenital Tract
 Chemosensitivity testing in gynaecological cancers

Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
French Fluent Medium Medium
Details Date From Date To
Member of European Association for Cancer Research. Member of Irish Association for Cancer Research
Abu Saadeh, F, Langhe R, Galvin DM, O Toole SA, O'Donnell DM, Gleeson N, Norris LA, Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy. , Thrombosis Research, 139, 2016, p135 - 141, Journal Article, PUBLISHED  DOI
Martin CM, Astbury K, Kehoe L, O'Crowley JB, O'Toole S, O'Leary JJ. , The Use of MYBL2 as a Novel Candidate Biomarker of Cervical Cancer. , Methods Mol Biol, 1249, 2015, p241 - 251, Journal Article, PUBLISHED
Langhe R, Norris L, Saadeh FA, Blackshields G, Varley R, Harrison A, Gleeson N, Spillane C, Martin C, O'Donnell DM, D'Arcy T, O'Leary J, O'Toole S, A novel serum microRNA panel to discriminate benign from malignant ovarian disease, Cancer Letters, 356, ((2ptB)), 2015, p628-636-, Journal Article, PUBLISHED  DOI
Busschots S, O'Toole S, O'Leary JJ, Stordal B, Non-invasive and non-destructive measurements of confluence in cultured adherent cell lines., MethodsX, 2, 2015, p8-13 , Journal Article, PUBLISHED
McEvoy LM, O'Toole SA, Spillane CD, Martin CM, Gallagher MF, Stordal B, Blackshields G, Sheils O, O'Leary JJ, Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer., BMC cancer, 15, 2015, p547 , Journal Article, PUBLISHED
Noninvasive Biomarkers in Ovarian Cancer in, editor(s)Debmalya Barh, Angelo Carpi, Mukesh Verma, Mehmet Gunduz , Cancer Biomarkers: Minimal and Noninvasive Early Diagnosis and Prognosis , CRC press, 2014, [O'Toole, SA, Ancuta, E, Langhe, R, Cahill, DJ, Murphy, M, Martin, C, McEvoy, L, Spillane, C, Sheils, O, Petricoin, E, Liotta, L, O'Leary JJ], Book Chapter, PUBLISHED
Keegan, Helen Pilkington, Loretto McInerney, Jamie Jeney, Csaba Benczik, Márta Cleary, Sinead von Bunau, Gunther Turner, Michael D'Arcy, Tom O' Toole, Sharon Borbála, Pal-Szenthe Borbála, Kaltenecker Johanna, Mózes Anettc, Kovács Agnes, Solt Bolger, Noel O'Leary, John Martin, Cara, Human papillomavirus detection and genotyping, by HC2, Full-Spectrum HPV and Molecular Beacon Real-Time HPV assay in an Irish colposcopy clinic, Journal of Virological Methods, 2014, Journal Article, PUBLISHED  TARA - Full Text
d'Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O'Crowley J, Haley K, Kernan N, Murphy C, Smyth PC, O'Byrne K, Pennington S, Cooke AA, Ffrench B, Martin CM, O'Donnell D, Hennessy B, Stordal B, Finn S, McCann A, Gleeson N, D'Arcy T, Flood B, O'Neill LA, Sheils O, O'Toole S, O'Leary JJ., The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer., PLoS One. , 9, (6), 2014, pe100816-, Journal Article, PUBLISHED  TARA - Full Text  DOI
Busschots S, O'Toole S, O'Leary JJ, Stordal B. , Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells, Experimental Cell Research, 2014, p1 - 14, Journal Article, PUBLISHED  TARA - Full Text  DOI
Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D'Arcy T, d'Adhemar C, Norris L, Langhe R, Saadeh FA, O'Leary JJ, O'Toole SA, Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening., International journal of molecular sciences, 14, (1), 2013, p2085-103 , Journal Article, PUBLISHED  TARA - Full Text
  

Page 1 of 4
Abu Saadeh F, O'Toole S, Gleeson N, Norris L, Peak ant-Xa levels following LMWH (tinzaparin) prophylaxis in gynaecological cancer patients post surgery, Thrombosis Research, 7th Internation Conference on Thrombosis & Hemostatis Issues in Cancer, , Bergamot Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014, Meeting Abstract, PUBLISHED
Ibrahim N, Norris L, O'Toole S, McHugh T, Gleeson N, Does extended thromboprophylaxis help reduce the incidence of venous thromboembolism in gynaecological cancer patients?, Thrombosis Research, 7th Internation Conference onal Thrombosis & Hemostatis Issues in Cancer,, Bergamo Italy, May 2014, edited by A Falanga, B. Brenner, F, Rickles , 133, (Suppl 2), Elsevier, 2014, Published Abstract, PUBLISHED
Abu Saadeh. F, Norris. L, O' Toole, Gleeson. N., Assessing the risk and mortality of venous thromboembolism in ovarian cancer., International Journal of Gynecological Cancer, 14th Biennial Meeting of the International Gynecological Cancer Society., Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, Meeting Abstract, PUBLISHED
Abu Saadeh F, Norris L, O'Toole S, Langhe R, O'Leary JJ, Gleeson N., Does tissue factor and tissue factor pathway inhibitor over-expression play a role in the development of venous thromboembolism in ovarian cancer patients?, Thrombosis Research, 6th International Conference on Thrombosis & Hemostasis Issues in Cancer, Bergamo Italy, April 2012, edited by A Falanga, B. Brenner, F, Rickles , 129, ((Suppl 1)), Elsevier, 2012, Published Abstract, PUBLISHED
Abu Saadeh. F, Norris. L, O' Toole. S, Langhe. R, O' Leary. J, Gleeson. N. , Why is venous thromboembolism is a common complication of ovarian cancer? , International Journal of Gynecological Cancer , 14th Biennial Meeting of the International Gynecological Cancer Society. , Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, Published Abstract, PUBLISHED
Abu Saadeh F, Norris L, O'Toole S, Langhe R, Gleeson N., Procoagulant activity in patients with gynecological malignancies and the effect of neoadjuvant chemotherapy , Thrombosis Research, 6th International Conference on Thrombosis & Hemostasis Issues in Cancer, Bergamo Italy, April 2012, edited by A Falanga, B. Brenner, F, Rickles , 129, (Suppl 1), Elsevier, 2012, Published Abstract, PUBLISHED
Abu Saadeh. F, Norris. L, O' Toole. S, Langhe. R, Gleeson. N, Endogenous thrombin potential as a marker for venous thrombosis in ovarian cancer., International Journal of Gynecological Cancer , 14th Biennial Meeting of the International Gynecological Cancer Society., Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, Published Abstract, PUBLISHED
Abu Saadeh. F, Norris. L, O' Toole. S, Langhe. R, Gleeson. N., ETP as a marker for venous thromboembolism in gynaecologial cancer patients post surgery, International Journal of Gynecological Cancer, 14th Biennial Meeting of the International Gynecological Cancer Society., Vancouver, Canada, October 2012, 22, (Suppl 3), 2012, Published Abstract, PUBLISHED
SA O'Toole, A Laios, BL Sheppard, NC Gleeson, T D'Arcy, EPJ McGuinness, J Bonnar, O Sheils and JJ O'Leary. , Potential predictors of chemotherapy response in ovarian cancer how do we define chemosensitivity?, Laboratory Investigation, United States and Canadian Society of Pathology, Atlanta, USA, Feb 2006, 86, (Suppl 1), Nature, 2006, pp190A , Meeting Abstract, PUBLISHED
A Laios, SA O'Toole, BL Sheppard, NC Gleeson, T D'Arcy, E PJ McGuinness, M Ring, O Sheils and JJ O'Leary, Molecular profiling of primary versus recurrent ovarian serous papillary adenocarcinomas. , Laboratory Investigation, United States and Canadian Society of Pathology, Atlanta, USA, Feb 2006, 86, (Suppl 1), Nature, 2006, pp185A , Meeting Abstract, PUBLISHED

  

Page 1 of 4
-Early diagnostics in ovarian cancer -Chemoresistance in ovarian cancer Chemosensitivity/Resistance testing of malignant gynaecological tumours -Examination of Fibrinolytic systems of malignant gynaecological tumours -Examination of angiogenesis in ovarian cancers. -Examination of multidrug resistance genes in gynaecological tumours. -Estrogen regulated genes in endometrial cancer. -PhytoSERMs and Endometrial Cancer